Neutron Holdings, Inc. (LIME)
Live price chart, market sentiment, and community perspectives for Neutron Holdings, Inc. (NASDAQ: LIME).
Live price chart, market sentiment, and community perspectives for Neutron Holdings, Inc. (NASDAQ: LIME).
On our desk, the LIME IPO looks like a textbook 'Hail Mary' that worked out just in time to avert default. While the valuation at a $1.69B market cap feels modest with an EV/Sales multiple around 1.4x, the street is intensely split. Bullish institutional coverage from Goldman Sachs highlights scale, but the ghosts of Bird's Chapter 11 filing in 2024 remind us how fast this asset-heavy micromobility space can unravel.
When evaluating LIME's operational metrics for our internal underwriting models, pay strict attention to fleet utilization and subscription mix. LimePass and LimePrime now make up about 40% of total revenue, which drives user retention and monthly active user growth up 22% to 5 million. Yet, this shift introduces margin compression pressures that analysts need to account for in out-year estimates.
Looking at the Q2 numbers closely, revenue rose 23.6% to $304.2M and adjusted EBITDA reached $84.2M, which looks solid on paper. However, reported net income of $295.4M was severely distorted by a $289.1M discrete tax benefit and the conversion of massive convertible notes. We need to strip out these one-off accounting boosts before assigning a sustainable free cash flow multiple.
Hedging with Q4 put spreads on LIME seems prudent given the severe seasonality of the electric bike and scooter rental market. Even though management guided Q3 revenue between $340M and $360M, winter weather headwinds in major megacities historically decimate asset productivity. I'm staying neutral-to-bearish until we see proof of multi-quarter structural profitability.
From a market psychology perspective, the muted debut—closing just 4% above the $25 IPO price—signals deep-seated investor skepticism toward venture-backed transportation tech coming off the 2021-2022 SPAC wreckage. Uber's ongoing backing provides a vital safety net, but public market investors are demanding concrete execution on cash flow before re-rating the stock toward Evercore's $40 target.
Explore plasma cleansing, somatic organ swaps, and BCI.